It's always our objective to support our scientists in the translation of basic science observations into benefits for patient and society
Dr. Sonja Schätzlein CF Technology Transfer / SPARK-FLI Program Manager

From Research to Application: Technology Transfer at FLI

It's crucial for the German research infrastructure to transfer new technologies, methods and intellectual property from research to application and commercial utilization. The revenues generated in this way may subsequently finance further research projects. Moreover, as an institute primarily funded by the federal and state government, our whole research and work should eventually be utilized for the benefit of the public.

At FLI, we do research on the foundation of phenomena and biological processes which as of now have not been described or fully understood. However, it's always our objective to identify and utilize potential targets for biomedical intervention, ultimately aiming at the development of novel therapeutic concepts for age-related diseases.

FLI's technology transfer is primarily focusing on two application fields: the provision of libraries and databases as well as the transfer of research findings into concrete cures.

To fully exploit potential industrial or biomedical/pharmaceutical applications derived from insights of FLI research, the Institute established the Core Facility Technology Transfer.


Technology

At FLI, internal and external competencies are bundled in an efficient structure for technology transfer, thus following the BMBF-granted Leibniz-guidelines to implement and strengthen technology transfer in research institutes. Internally, the research coordinator and the legal department have responsibility for this matter. For the exploitation of its intellectual property, FLI collaborates with Ascenion, an exclusive technology transfer partner within life sciences.

Examples for transfer projects from relevant research findings at FLI:

  • Cell wall-less bacteria (L-forms) for high yield heterologous protein expression (LINK)

  • GFP transgenic zebrafish strain as tool for studying kidney development (LINK)

  • PARP1 -/- mice: an animal model for cancer, autoimmune encephalomyelitis, arthritis and diabetes (LINK)

  • Innovative nerve sheath tumor therapy (LINK)

New technologies:

  • KILAPE – Automated scaffolding and gap filling of large, complex genomes (LINK)

  • High quality tubulin and microtubule-associated proteins: tau, MAP1 and MAP2 as research tools (LINK)

  • Novel treatment or prevention of age-related diseases extending lifespan (LINK)

  • UV-Fit – increasing metabolic fitness and reducing body weight without fasting (LINK)

  • Lifespan predictor - Reliable deep learning tool for in vivo lifespan prediction (LINK)

  • VAFD - Nutritional compositions for treating dysfunction of liver fat metabolism (LINK)

Contact

Dr. Sonja Schätzlein

Core Facility Manager

PD Dr. Wilfried Briest

Head of Research Coordination